DexCom, Inc. $DXCM Stock: Motley Fool Asset Management LLC Reduces Position

Motley Fool Asset Management LLC trimmed its holdings in DexCom, Inc. (NASDAQ:DXCM) by 4.9% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 195,487 shares of the medical device company’s stock after selling 10,114 shares during the period. DexCom comprises approximately 0.6% of Motley Fool Asset Management LLC’s holdings, making the stock its 28th largest holding. Motley Fool Asset Management LLC’s holdings in DexCom were worth $16,869,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Legal & General Group Plc bought a new stake in shares of DexCom in the second quarter worth $173,237,000. Deutsche Bank AG bought a new position in DexCom during the 2nd quarter valued at $164,035,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in DexCom by 15.6% during the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 11,261,876 shares of the medical device company’s stock valued at $758,487,000 after acquiring an additional 1,515,702 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. bought a new position in DexCom during the 2nd quarter valued at $89,940,000. Finally, Arrowstreet Capital Limited Partnership grew its holdings in DexCom by 100.4% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 2,545,103 shares of the medical device company’s stock worth $159,832,000 after acquiring an additional 1,275,142 shares in the last quarter. 97.75% of the stock is currently owned by hedge funds and other institutional investors.

DexCom Trading Up 0.1%

Shares of NASDAQ DXCM opened at $78.62 on Thursday. The company has a market cap of $29.67 billion, a price-to-earnings ratio of 31.08, a price-to-earnings-growth ratio of 1.31 and a beta of 1.48. DexCom, Inc. has a 12-month low of $54.11 and a 12-month high of $92.59. The company has a current ratio of 1.73, a quick ratio of 1.43 and a debt-to-equity ratio of 0.47. The stock’s 50 day simple moving average is $86.18 and its 200 day simple moving average is $74.54.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings data on Thursday, July 30th. The medical device company reported $0.70 EPS for the quarter, topping analysts’ consensus estimates of $0.61 by $0.09. DexCom had a return on equity of 35.94% and a net margin of 20.12%. The firm had revenue of $1.31 billion during the quarter, compared to the consensus estimate of $1.29 billion. During the same period in the prior year, the business earned $0.48 EPS. The firm’s revenue was up 13.1% on a year-over-year basis. Equities research analysts expect that DexCom, Inc. will post 2.64 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the stock. Wells Fargo & Company boosted their target price on shares of DexCom from $85.00 to $90.00 and gave the stock an “overweight” rating in a research report on Friday, July 31st. UBS Group set a $96.00 price target on shares of DexCom and gave the stock a “buy” rating in a research report on Tuesday, July 28th. Mizuho set a $100.00 price target on DexCom in a research note on Tuesday, October 13th. TD Cowen reiterated a “buy” rating and issued a $95.00 price target on shares of DexCom in a research note on Friday, September 18th. Finally, Piper Sandler reissued an “overweight” rating and issued a $95.00 price objective (up from $88.00) on shares of DexCom in a report on Friday, July 31st. Three research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $92.43.

Insider Buying and Selling

In other news, EVP Michael Brown sold 1,700 shares of the business’s stock in a transaction on Thursday, October 15th. The shares were sold at an average price of $85.48, for a total transaction of $145,316.00. Following the completion of the transaction, the executive vice president owned 98,185 shares of the company’s stock, valued at approximately $8,392,853.80. The trade was a 1.70% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mark Foletta sold 2,000 shares of the company’s stock in a transaction dated Monday, August 3rd. The stock was sold at an average price of $85.32, for a total transaction of $170,640.00. Following the transaction, the director owned 48,852 shares of the company’s stock, valued at $4,168,052.64. This represents a 3.93% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 26,822 shares of company stock valued at $2,250,833 in the last three months. 0.28% of the stock is owned by corporate insiders.

DexCom Profile

DexCom, Inc develops and commercializes continuous glucose monitoring (CGM) systems for people with diabetes. Its devices use a small wearable sensor to measure glucose levels in real time and transmit readings to compatible smartphones, receivers, smartwatches, and other connected devices, helping users monitor glucose trends and make informed decisions about their health.

The company’s product portfolio includes the Dexcom G7 and Dexcom G6 CGM systems, as well as Dexcom ONE and Dexcom ONE+ products offered in select markets.